Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
IRVINE, Calif.
Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression
Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression
DUBLIN and BUDAPEST, Hungary, Dec.
Parkinson's: Could this existing drug halt disease progression?
Parkinson's: Could this existing drug halt disease progression?
Researchers have discovered that a molecule in the tapeworm drug niclosamide might be able to protect against Parkinson's disease-related neuronal damage.
Another patent challenge for Gilead, this time in China
Another patent challenge for Gilead, this time in China
A legal challenge against Gilead Sciences’ (Nasdaq.
Alnylam and Sanofi cleared to resume hemophilia candidate trials
Alnylam and Sanofi cleared to resume hemophilia candidate trials
The US Food and Drug Administration has lifted the hold on clinical studies with fitusiran, including the Phase II open-label extension (OLE) study and the ATLAS Phase III program.
EU drugs agency says move to new HQ may take longer
EU drugs agency says move to new HQ may take longer
LONDON (Reuters) - The European drugs agency said on Friday its new headquarters in Amsterdam may not be ready by the time it has to leave London due to Brexit because the building will not be...
Lupin’s Safyral generic Tydemy gets FDA nod
Lupin’s Safyral generic Tydemy gets FDA nod
The Food and Drug Administration has approved Mumbai-based Lupin’s Tydemy.
Pfizer weighs 'strategic options' for newly FDA-approved Remicade biosim, its second
Pfizer weighs 'strategic options' for newly FDA-approved Remicade biosim, its second
Pfizer is already working to pick up market share with Inflectra, the first biosimilar to Johnson & Johnson's blockbuster immunology med Remicade, but now the company has a second copycat boas...
Perrigo lines up bid for Merck's consumer health unit: sources
Perrigo lines up bid for Merck's consumer health unit: sources
LONDON/FRANKFURT (Reuters) - Generic drugmaker Perrigo has decided to enter the fray for Merck KGaA’s consumer health unit, sources told Reuters, and is preparing an indicative offer for the...
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As).
Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer
Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer
Despite being late to market, the collaborators hope a new indication could help boost its prospects.
Needle-free injection device moves closer to market
Needle-free injection device moves closer to market
Needles are usually seen as a necessary evil, but maybe they don't have to be.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand